Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis

Table 2 Demographic and baseline clinical characteristics of MS patients and healthy controls included in the ELISA study

Baseline characteristics	HC	MS ^d	RRMS	SPMS	PPMS
Number of patients	18	37	13	14	10
Age (years)	42.8 (10.6)	43.6 (9.7)	36.0 (8.0)	44.7 (7.6)	51.9 (6.5)
Female/male (% women)	9/9 (50.0)	22/15 (59.5)	8/5 (61.5)	9/5 (64.3)	5/5 (50.0)
Duration of disease (years)	-	8.3 (5.0)	6.1 (4.4)	8.8 (4.0)	10.1 (5.6)
EDSS^a	-	3.9 (2.3-5.3)	2.2 (1.5-3.0)	4.5 (4.0-5.1)	5.4 (4.3-6.5)
Number of relapses^b	-	1.1 (0.9)	1.6 (0.8)	0.6 (0.8)	-
Number of Gd-enhancing lesions^c	-	1.4 (2.8)	1.7 (3.2)	1.0 (2.2)	-

Data are expressed as mean (standard deviation) unless otherwise stated. ^aData are expressed as mean (interquartile range). ^bRefers to the number of relapses in the two previous years of blood extraction. ^cRefers to the number of gadolinium-enhancing lesions at the time of blood extraction. ^dOne SPMS patient had a history of concomitant gastritis. One RRMS patient received corticosteroid treatment within the month prior to blood extraction for protein determination. Information is missing for five patients (four PPMS and one SPMS). MS: refers to the whole group of MS patients. EDSS: Expanded Disability Status Scale. RRMS: relapsing-remitting MS. SPMS: secondary progressive MS. PPMS: primary progressive MS. HC: healthy controls.

ISSN: 1742-2094